Karyopharm Therapeutics reported $62.54M in Current Liabilities for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
Amgen AMGN:US $ 12618M 268M
Astrazeneca AZN:US $ 21815M 925M
AstraZeneca AZN:LN 1791796.84M 60282.28M
Avrobio Inc AVRO:US $ 12.78M 4.34M
Bristol Myers Squibb BMY:US $ 20915M 1906M
Eli Lilly And LLY:US $ 15620.6M 2234.6M
Enanta Pharmaceuticals ENTA:US $ 23.04M 7.7M
Epizyme EPZM:US $ 34.95M 4.01M
GlaxoSmithKline GSK:LN 3783500M 1355700M
Karyopharm Therapeutics KPTI:US $ 62.54M 3.8M
Macrogenics MGNX:US $ 50.88M 16.22M
Mirati Therapeutics MRTX:US $ 119.15M 4.42M
Nektar Therapeutics NKTR:US $ 104.98M 0.3M
Novartis NOVN:VX SF 27646M 2161M
Novartis NVS:US $ 27646M 2161M
Regeneron Pharmaceuticals REGN:US $ 3033.9M 26.3M
Sangamo Biosciences SGMO:US $ 119.99M 1.46M
Takeda 4502:JP Y 2166942M 21212M
Ultragenyx Pharmaceutical RARE:US $ 220.64M 53.4M
Xencor XNCR:US $ 75.04M 14.1M
YTE INCY:US $ 926.67M 40.51M